Cellmid is actively seeking partners for the development of its midkine protein and midkine antagonist product portfolio.  

Midkine has been shown to be a mediator and/or modulator of various inflammatory pathways and as such has been implicated in a number of inflammatory and autoimmune diseases. Key disease indications where midkine have been validated to be a significant target are multiple sclerosis and rheumatoid arthritis.   

Early validation data suggests that midkine is also involved in the development and spread of a large number of cancers. A midkine antagonist drug may be useful in the treatment of chemotherapy resistance or as part of a strategy to prevent metastasis of certain cancers.   

Midkine’s protective characteristic of reducing cell suicide (apoptosis) following an ischemic event has been demonstrated in large animal models. Ischemic diseases can affect a number of organs including the heart (AMI or heart attack), brain (stroke), eyes (optic nerve stroke), kidneys (renal ischemia) and liver.    

A therapeutic approach to administer midkine protein to prevent tissue damage following ischemia may be useful to improve survival rates and recovery following AMI and other ischemic events.